TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer June 27, 2014